Video
Dr. Kris on the EML4-ALK Translocation in Lung Cancer
Author(s):
Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York on the EML4-ALK Translocation
Mark G. Kris, MD, Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, discusses how the crizotinib clinical trial changed the paradigm for treating patients with lung cancer who harbor an EML4-ALK translocation, at the 2010 ASCO Annual Meeting.
On August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non—small cell lung cancer (NSCLC).
Related Videos
Related Content
